| Halaven (eribulin mesylate) / Eisai |
ChiCTR2100053594: Efficacy and safety of eribulin monotherapy or combination therapy in Chinese adults with soft tissue sarcoma |
|
|
| Not yet recruiting | N/A | | | Anthracycline-based drugs ;Ifosfamide-based ;Other chemotherapy options ;Combined molecular targeted therapy ;Combination immune checkpoint inhibitor therapy | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, self-funded | soft tissue sarcoma (STS) | | | | |
ERI-Based-01, NCT05953909: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (). |
|
|
| Active, not recruiting | N/A | 120 | RoW | Eribulin-Based Regimen, Not Applicable since observational study, nab-paclitaxel based regimen, Other Chemotherapy Regimen | Fujian Cancer Hospital | Breast Cancer | 08/23 | 08/23 | | |
ChiCTR2100043105: Treatment of physician's choice, Pyrotinib combined with Trastuzumab among HER 2 positive breast cancer who are no response after receiving the neoadjuvant Trastuzumab and Pertuzumab regimens: a single-arm, multi-centre clinical exploratory study |
|
|
| Recruiting | N/A | 30 | | Pyrotinib, Capecitabine or Vinorelbine or Eribulin, combined with Trastuzumab | The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | Breast cancer | | | | |
| Recruiting | N/A | 200 | Europe | | University of Milano Bicocca, EISAI s.r.l. | Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer | 12/23 | 12/23 | | |
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy |
|
|
| Terminated | N/A | 5 | US | Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Cancer, Breast Neoplasms | 02/24 | 02/24 | | |
| Recruiting | N/A | 1350 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer | 06/27 | 09/28 | | |
